Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States

• Status: Withdrawn
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, daylight PDT will be administered to interested patients at Dana-Farber/Brigham and Women's Cancer Center. Daylight PDT has been shown to be an effective and painless alternative to traditional PDT. Daylight PDT involves application of the photosensitizer in the physician's office followed by exposure to daylight.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Aminolevulinic Acid

Criteria

Inclusion Criteria:

• Patients ≥ 18 years referred for the treatment of 5 or more visible or palpable actinic keratoses on one treatment area

Exclusion Criteria:

• Age less than 18 years of age.

• Pregnant women.

• Non-English speaking patients.

• Treatment of actinic keratoses with other modalities including topical 5-fluorouracil, topical imiquimod, conventional PDT, alpha-hydroxy-acids, and glycolic acids within 2 months

• Use of retinoids within 1 month

• Use of the following medications: griseofulvin, thiazide diuretics, sulfonyureas, phenothiazines, sulfonamides, and tetracyclines

• History of cutaneous photosensitivity, lupus, porphyrias, or any other photosensitizing condition